Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

roche.com

Investor Update

Get the latest updates from Investor Update directly as they happen.

Follow now 352 followers

Latest posts

Last updated 3 minutes ago

Reminder: Invitation to Roche’s Virtual Ophthalmology Investor Event

5 minutes ago

We are pleased to invite investors and analysts to participate in our...

Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology

about 19 hours ago

Rules out Alzheimer’s pathology in early stages to enhance diagnostic pathway efficiencyProvides...

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

1 day ago

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...

Invitation to Roche’s Virtual Ophthalmology Investor Event

11 days ago

We are pleased to invite investors and analysts to participate in our...

Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

14 days ago

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy...

Invitation to Roche’s 3rd Quarter Sales 2025 Presentation

21 days ago

  Roche will publish its Sales for the 3rd Quarter of 2025 prior...

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

22 days ago

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in...

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

25 days ago

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients...

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

26 days ago

89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe...

Reminder: Invitation to Roche’s Pharma Day 2025

28 days ago

  The Roche Investor Relations team would like to invite you to the...